{"pmid":32235915,"title":"COVID-19: a new challenge for human beings.","text":["COVID-19: a new challenge for human beings.","Cell Mol Immunol","Yang, Penghui","Wang, Xiliang","32235915"],"journal":"Cell Mol Immunol","authors":["Yang, Penghui","Wang, Xiliang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32235915","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41423-020-0407-x","source":"PubMed","topics":["Mechanism","Diagnosis","Prevention","Treatment"],"weight":1,"_version_":1662996001751826432,"score":7.6048946,"similar":[{"pmid":32023682,"title":"[2019-nCoV: new challenges from coronavirus].","text":["[2019-nCoV: new challenges from coronavirus].","The outbreak of pneumonia caused by the novel coronavirus 2019-nCoV in Wuhan, Hubei province of China, at the end of 2019 shaped tremendous challenges to China's public health and clinical treatment. The virus belongs to the beta genus Coronavirus in the family Corornaviridae, and is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia. The virus is transmitted through droplets, close contact, and other means, and patients in the incubation period could potentially transmit the virus to other persons. According to current observations, 2019-nCoV is weaker than SARS in pathogenesis, but has stronger transmission competence; it's mechanism of cross-species spread might be related with angiotensin-converting enzyme (ACE2), which is consistent with the receptor SARS-CoV. After the outbreak of this disease, Chinese scientists invested a lot of energy to carry out research by developing rapid diagnostic reagents, identifying the characters of the pathogen, screening out clinical drugs that may inhibit the virus, and are rapidly developing vaccines. The emergence of 2019-nCoV reminds us once again of the importance of establishing a systematic coronavirus surveillance network. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research.","Zhonghua Yu Fang Yi Xue Za Zhi","Tian, H Y","32023682"],"abstract":["The outbreak of pneumonia caused by the novel coronavirus 2019-nCoV in Wuhan, Hubei province of China, at the end of 2019 shaped tremendous challenges to China's public health and clinical treatment. The virus belongs to the beta genus Coronavirus in the family Corornaviridae, and is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia. The virus is transmitted through droplets, close contact, and other means, and patients in the incubation period could potentially transmit the virus to other persons. According to current observations, 2019-nCoV is weaker than SARS in pathogenesis, but has stronger transmission competence; it's mechanism of cross-species spread might be related with angiotensin-converting enzyme (ACE2), which is consistent with the receptor SARS-CoV. After the outbreak of this disease, Chinese scientists invested a lot of energy to carry out research by developing rapid diagnostic reagents, identifying the characters of the pathogen, screening out clinical drugs that may inhibit the virus, and are rapidly developing vaccines. The emergence of 2019-nCoV reminds us once again of the importance of establishing a systematic coronavirus surveillance network. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Tian, H Y"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023682","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0253-9624.2020.0001","keywords":["2019-nCoV","Coronavirus","Public health"],"source":"PubMed","locations":["China","Hubei","Chinese","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Prevention","Transmission","Treatment"],"weight":1,"_version_":1663095626251894785,"score":67.0044},{"pmid":32037473,"title":"New coronavirus: new challenges for pediatricians.","text":["New coronavirus: new challenges for pediatricians.","World J Pediatr","Chen, Zhi-Min","Fu, Jun-Fen","Shu, Qiang","32037473"],"journal":"World J Pediatr","authors":["Chen, Zhi-Min","Fu, Jun-Fen","Shu, Qiang"],"date":"2020-02-11T11:00:00Z","year":2020,"_id":"32037473","week":"20207|Feb 10 - Feb 16","doi":"10.1007/s12519-020-00346-4","source":"PubMed","topics":["Diagnosis","Treatment","Prevention"],"weight":1,"_version_":1663095626233020416,"score":60.30753},{"pmid":32098422,"pmcid":"PMC7077191","title":"Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV.","text":["Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV.","After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections. Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes acute lung symptoms, leading to a condition that has been named as \"coronavirus disease 2019\" (COVID-19). The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security. There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses. The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms.","Viruses","Xu, Jiabao","Zhao, Shizhe","Teng, Tieshan","Abdalla, Abualgasim Elgaili","Zhu, Wan","Xie, Longxiang","Wang, Yunlong","Guo, Xiangqian","32098422"],"abstract":["After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections. Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes acute lung symptoms, leading to a condition that has been named as \"coronavirus disease 2019\" (COVID-19). The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security. There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses. The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms."],"journal":"Viruses","authors":["Xu, Jiabao","Zhao, Shizhe","Teng, Tieshan","Abdalla, Abualgasim Elgaili","Zhu, Wan","Xie, Longxiang","Wang, Yunlong","Guo, Xiangqian"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32098422","week":"20209|Feb 24 - Mar 01","doi":"10.3390/v12020244","keywords":["*SARS-CoV","*SARS-CoV-2","*clinical manifestations","*coronaviruses","*genomic comparison","*pathogenic mechanism","*proteomic comparison"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1663095626153328640,"score":56.07901},{"pmid":32234465,"title":"Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment.","text":["Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment.","Viral respiratory diseases such as the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), always pose severe threat to people. First identified in the late December 2019, in Wuhan, China, a novel coronavirus (2019-nCoV) has rampantly spread to lots of provinces in China, and multiple countries are affected. The viral outbreaks have stirred panic and emergency on public health around the world and the number of infections continues to rise. But the cause and consequence of the pneumonia still remain unknown. In order to effectively implement the epidemic prevention, early identification and diagnosis is critical to disease control. Herein we scrutinize a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options of 2019 novel coronavirus pneumonia, also propose potential strategies for preventing the infection.","Int J Antimicrob Agents","Kang, Shuntong","Peng, Wenyao","Zhu, Yuhao","Lu, Shiyao","Zhou, Min","Lin, Wei","Wu, Wenfang","Huang, Shu","Jiang, Liping","Luo, Xuan","Deng, Meichun","32234465"],"abstract":["Viral respiratory diseases such as the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), always pose severe threat to people. First identified in the late December 2019, in Wuhan, China, a novel coronavirus (2019-nCoV) has rampantly spread to lots of provinces in China, and multiple countries are affected. The viral outbreaks have stirred panic and emergency on public health around the world and the number of infections continues to rise. But the cause and consequence of the pneumonia still remain unknown. In order to effectively implement the epidemic prevention, early identification and diagnosis is critical to disease control. Herein we scrutinize a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options of 2019 novel coronavirus pneumonia, also propose potential strategies for preventing the infection."],"journal":"Int J Antimicrob Agents","authors":["Kang, Shuntong","Peng, Wenyao","Zhu, Yuhao","Lu, Shiyao","Zhou, Min","Lin, Wei","Wu, Wenfang","Huang, Shu","Jiang, Liping","Luo, Xuan","Deng, Meichun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234465","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105950","keywords":["Detection","Mechanism","Novel coronavirus","Treatment"],"source":"PubMed","locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1662996001673183232,"score":50.6621},{"pmid":32227090,"title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.","text":["The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.","A new type of pneumonia caused by a novel coronavirus SARS-CoV-2 outbreaks recently in China and spreads into many other countries. This disease, named as COVID-19, is similar to patients infected by SARS-CoV and MERS-CoV, and nearly 20% of patients developed severe condition. Cardiac injury is a prevalent complication of severe patients, exacerbating the disease severity in coronavirus disease 2019 (COVID-19) patients. Angiotensin-converting enzyme 2 (ACE2), the key host cellular receptor of SARS-CoV-2, has been identified in multiple organs, but its cellular distribution in human heart is not illuminated clearly. This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition. The finding of this study explains the high rate of severe cases among COVID-19 patients with basic cardiovascular disease; and these results also perhaps provide important reference to clinical treatment of cardiac injury among severe patients infected by SARS-CoV-2.","Cardiovasc Res","Chen, Liang","Li, Xiangjie","Chen, Mingquan","Feng, Yi","Xiong, Chenglong","32227090"],"abstract":["A new type of pneumonia caused by a novel coronavirus SARS-CoV-2 outbreaks recently in China and spreads into many other countries. This disease, named as COVID-19, is similar to patients infected by SARS-CoV and MERS-CoV, and nearly 20% of patients developed severe condition. Cardiac injury is a prevalent complication of severe patients, exacerbating the disease severity in coronavirus disease 2019 (COVID-19) patients. Angiotensin-converting enzyme 2 (ACE2), the key host cellular receptor of SARS-CoV-2, has been identified in multiple organs, but its cellular distribution in human heart is not illuminated clearly. This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition. The finding of this study explains the high rate of severe cases among COVID-19 patients with basic cardiovascular disease; and these results also perhaps provide important reference to clinical treatment of cardiac injury among severe patients infected by SARS-CoV-2."],"journal":"Cardiovasc Res","authors":["Chen, Liang","Li, Xiangjie","Chen, Mingquan","Feng, Yi","Xiong, Chenglong"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227090","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cvr/cvaa078","keywords":["ACE2","Heart failure","Heart injury","SARS-CoV-2"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1662819280248373248,"score":48.739307}]}